

# Christopher A Mecoli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3079828/publications.pdf>

Version: 2024-02-01

37  
papers

613  
citations

567247

15  
h-index

677123

22  
g-index

42  
all docs

42  
docs citations

42  
times ranked

833  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk Factors for Infection and Health Impacts of the Coronavirus Disease 2019 (COVID-19) Pandemic in People With Autoimmune Diseases. <i>Clinical Infectious Diseases</i> , 2022, 74, 427-436.	5.8	15
2	Prevalence of avascular necrosis in idiopathic inflammatory myopathies: a single-centre experience. <i>Rheumatology</i> , 2022, 61, 936-942.	1.9	2
3	Performance of the 2017 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Idiopathic Inflammatory Myopathies in Patients With <scp>Myositisâ€špecific</scp> Autoantibodies. <i>Arthritis and Rheumatology</i> , 2022, 74, 508-517.	5.6	24
4	Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	26
5	Perifollicular Hypopigmentation in Systemic Sclerosis: Associations With Clinical Features and Internal Organ Involvement. <i>Journal of Rheumatology</i> , 2022, 49, 475-481.	2.0	3
6	IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function. <i>JCI Insight</i> , 2022, 7, .	5.0	23
7	Presence and Implications of <scp>Antiâ€šAngiotensin Converting Enzymeâ€š</scp> Immunoglobulin M Antibodies in <scp>Antiâ€šMelanomaâ€šDifferentiationâ€šAssociated</scp> 5 Dermatomyositis. <i>ACR Open Rheumatology</i> , 2022, 4, 457-463.	2.1	4
8	Effect of mycophenolate mofetil dose on antibody response following initial SARS-CoV-2 vaccination in patients with systemic sclerosis. <i>Lancet Rheumatology</i> , The, 2022, 4, e462-e464.	3.9	6
9	Advances at the interface of cancer and systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 50-57.	1.7	4
10	Cancer in Systemic Sclerosis: Analysis of Antibodies Against Components of the Th/To Complex. <i>Arthritis and Rheumatology</i> , 2021, 73, 315-323.	5.6	19
11	PM-Scl and Th/To in systemic sclerosis: a comparison of different autoantibody assays. <i>Clinical Rheumatology</i> , 2021, 40, 2763-2769.	2.2	5
12	A North American Cohort of Antiâ€šSAE Dermatomyositis: Clinical Phenotype, Testing, and Review of Cases. <i>ACR Open Rheumatology</i> , 2021, 3, 287-294.	2.1	28
13	Clinical and Molecular Phenotyping in Scleromyxedema Pretreatment and Posttreatment With Intravenous Immunoglobulin. <i>Arthritis Care and Research</i> , 2020, 72, 761-767.	3.4	13
14	Myositis Autoantibodies: A Comparison of Results From the Oklahoma Medical Research Foundation Myositis Panel to the Euroimmun Research Line Blot. <i>Arthritis and Rheumatology</i> , 2020, 72, 192-194.	5.6	34
15	More Than Skin Deep: Bringing Precision Medicine to Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 383-385.	5.6	3
16	Validation of anti-Mi2 autoantibody testing by line blot. <i>Autoimmunity Reviews</i> , 2020, 19, 102425.	5.8	6
17	Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1). <i>Clinical Rheumatology</i> , 2020, 39, 1199-1205.	2.2	6
18	The Utility of Plasma Vascular Biomarkers in Systemic Sclerosis: A Prospective Longitudinal Analysis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1341-1349.	5.6	3

#	ARTICLE	IF	CITATIONS
19	Assessing the content validity of patient-reported outcome measures in adult myositis: A report from the OMERACT myositis working group. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 943-948.	3.4	6
20	<i>Pneumocystis jirovecii</i> Pneumonia and Other Infections in Idiopathic Inflammatory Myositis. <i>Current Rheumatology Reports</i> , 2020, 22, 7.	4.7	5
21	Ultrasound can differentiate inclusion body myositis from disease mimics. <i>Muscle and Nerve</i> , 2020, 61, 783-788.	2.2	21
22	More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies. <i>Neurology</i> , 2019, 93, e1768-e1777.	1.1	35
23	Evaluation of risk factors for pseudo-obstruction in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 405-410.	3.4	15
24	The ILD-GAP risk prediction model performs poorly in myositis-associated interstitial lung disease. <i>Respiratory Medicine</i> , 2019, 150, 63-65.	2.9	13
25	OMERACT 2018 Modified Patient-reported Outcome Domain Core Set in the Life Impact Area for Adult Idiopathic Inflammatory Myopathies. <i>Journal of Rheumatology</i> , 2019, 46, 1351-1354.	2.0	23
26	Sonographic findings from inflammatory arthritis due to antisynthetase syndrome. <i>Clinical Rheumatology</i> , 2019, 38, 1477-1483.	2.2	8
27	Patient-Reported Outcomes in Adult Idiopathic Inflammatory Myopathies. <i>Current Rheumatology Reports</i> , 2019, 21, 62.	4.7	11
28	Cancer and Idiopathic Inflammatory Myositis. <i>Current Treatment Options in Rheumatology</i> , 2019, 5, 231-241.	1.4	2
29	Perceptions of Patients, Caregivers, and Healthcare Providers of Idiopathic Inflammatory Myopathies: An International OMERACT Study. <i>Journal of Rheumatology</i> , 2019, 46, 106-111.	2.0	25
30	Management of Interstitial Lung Disease in Patients With Myositis Specific Autoantibodies. <i>Current Rheumatology Reports</i> , 2018, 20, 27.	4.7	25
31	An update on autoantibodies in scleroderma. <i>Current Opinion in Rheumatology</i> , 2018, 30, 548-553.	4.3	21
32	Vascular complications in systemic sclerosis: a prospective cohort study. <i>Clinical Rheumatology</i> , 2018, 37, 2429-2437.	2.2	15
33	“Hiker’s feet”: a novel cutaneous finding in the inflammatory myopathies. <i>Clinical Rheumatology</i> , 2017, 36, 1683-1686.	2.2	36
34	Advancing the Development of Patient-reported Outcomes for Adult Myositis at OMERACT 2016: An International Delphi Study. <i>Journal of Rheumatology</i> , 2017, 44, 1683-1687.	2.0	21
35	NXP-2 Positive Dermatomyositis: A Unique Clinical Presentation. <i>Case Reports in Rheumatology</i> , 2017, 1-4.	0.6	9
36	<i>Pneumocystis jirovecii</i> pneumonia in rheumatic disease: a 20-year single-centre experience. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 671-673.	0.8	37

#	ARTICLE	IF	CITATIONS
37	The DNA sensors AIM2 and IFI16 are SLE autoantigens that bind neutrophil extracellular traps. <i>ELife</i> , 0, 11, .	6.0	23